Sugi Predict

Sugi Predict / Compounds / SCHEMBL323257

SCHEMBL323257

SCHEMBL323257

COc1ccc(CN(c2ccncn2)S(=O)(=O)c2cc(Cl)c(F)cc2F)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.39
▸ CYP1A2 P05177 4/20 0.37
▸ CYP3A4 P08684 4/20 0.37
▸ CYP2D6 P10635 4/20 0.37
▸ CYP2C19 P33261 4/20 0.37
▸ TSHR P16473 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ GAA P10253 2/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ TP53 P04637 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MEN1 O00255 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14934588 0.92 POLB (0.41) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL29481979 0.92 POLB (0.41) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20238577 0.92 POLB (0.37) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20095675 0.92 POLB (0.37) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL29669041 0.92 POLB (0.37) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20252647 0.92 ALDH1A1 (0.33) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL15465475 0.91 CYP1A2 (0.39) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20485937 0.91 KDM4E (0.42) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL15464432 0.90 POLB (0.39) POLBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL15463758 0.89 POLB (0.39) POLBCYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239766-A1 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS GENENTECH, INC. (US) 2024-07-18 — — US disclosed
WO-2023028056-A1 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS GENENTECH, INC. (US) 2023-03-02 — — WO disclosed
CN-110325531-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2022-05-27 — — CN disclosed
US-20220081423-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-03-17 — — US disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 — — US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 — — US disclosed
US-11028075-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-06-08 — — US disclosed
US-11028075-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-06-08 — — US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 — — US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 — — US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 — — US disclosed
US-20140045862-A1 Cycloalkane Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-13 — — US disclosed
EP-2590951-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-15 — — EP disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239766-A1 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS CACNA1E, TRPV1, SCN3A POLB 4728/4885CYP1A2 2951/4885CYP3A4 4002/4885
US-20220081423-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF TRPV1, HCN4, TRPA1 POLB 4466/4885CYP1A2 2059/4885CYP3A4 1543/4885
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D POLB 3375/4885CYP1A2 831/4885CYP3A4 414/4885
US-20120010182-A1 Chemical Compounds SCN1A, SCN1B, CACNA1E POLB 4229/4885CYP1A2 643/4885CYP3A4 849/4885
US-11028075-B2 Therapeutic compounds and methods of use thereof TRPV1, HCN4, TRPA1 POLB 4466/4885CYP1A2 2059/4885CYP3A4 1543/4885
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B POLB 3810/4885CYP1A2 926/4885CYP3A4 396/4885
US-20140045862-A1 Cycloalkane Derivatives TRPV1, TRPA1, SCNN1A POLB 3201/4885CYP1A2 2162/4885CYP3A4 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.